20 Dec 2024 - 20 Dec 2025
09:00 AM - 09:00 PM
8th annual year ended review in lung cancer 2024
Program Director: Undiscolosed
Day 1 Sessions
Date : 20 Dec 2024
| ESMO 1538O Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study | 09:30 AM - 09:40 AM |
| Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study | 09:40 AM - 09:47 AM |
| Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study | 09:47 AM - 09:54 AM |
| Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma | 09:54 AM - 10:01 AM |
| Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. | 10:01 AM - 10:08 AM |
| MA03.03 The Impact of AI-driven 3D Reconstruction on Pulmonary Surgery Planning (AIR-SURGE): A Multi-Center Multi-Reader Multi-Case Study (WCLC 2024) | 10:08 AM - 10:15 AM |
| MA03.07 Outcomes of Older Patients in CALGB 140503 (Alliance): Lobar vs Sublobar Resection for Peripheral Stage IA Non-Small Cell Lung Cancer [WCLC 2024] | 10:15 AM - 10:22 AM |
| Integrating IO in management of early lung-in both operative and inoperative setting. | 10:22 AM - 10:52 AM |
| Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671) | 11:22 AM - 11:32 AM |
| NEOTORCH Trial: Perioperative Toripalimab + Chemo in Resectable NSCLC – Phase 3 Results. | 11:32 AM - 11:39 AM |
| RATIONALE-315: Neoadjuvant Tislelizumab + Chemo in Resectable NSCLC – ESMO 2024 Results | 11:39 AM - 11:46 AM |
| AEGEAN Trial: Perioperative Durvalumab & ctDNA Clearance in Resectable NSCLC | 11:46 AM - 11:56 AM |
| NADIM Trial: 5-Year Outcomes of Perioperative Nivolumab + Chemo in Stage III NSCLC | 11:56 AM - 12:03 PM |
| ALNEO Trial: Neoadjuvant Alectinib in Resectable Stage III ALK+ NSCLC – WCLC 2024 Interim Data. | 12:10 PM - 12:17 PM |
| ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024 | 12:17 PM - 12:24 PM |
| Combining Local & Systemic Therapy in NSCLC: Perioperative, Neoadjuvant & Adjuvant Strategies | 12:24 PM - 01:00 AM |
| Breakthrough in Stage III NSCLC: NRG-RTOG 1106 Adaptive Radiotherapy Trial Results (JCO 2024) | 02:00 AM - 02:07 AM |
| SEISMIC Trial Results: Endoscopic Mediastinal Staging to Guide Radiotherapy in NSCLC | 02:07 AM - 02:14 AM |
| NRG LU008 Trial: SBRT + Chemoradiation for Locally Advanced NSCLC | Phase III Results (JTO) | 02:14 AM - 02:21 AM |
| ESMO 2024: Beclomethasone Inhalation with Radiotherapy in LA-NSCLC | 1242MO Phase II Trial | 02:21 AM - 02:28 AM |
| LAURA Trial (NEJM/ASCO 2024): Osimertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC | 02:08 AM - 02:35 AM |
| POLESTAR Trial (WCLC 2024): Aumolertinib After Chemoradiotherapy in Stage III EGFR+ NSCLC | 02:35 AM - 02:42 AM |
| PACIFIC-2 Final Results | Durvalumab + Chemoradiotherapy in Stage III NSCLC | ELCC 2024 | 02:42 AM - 02:49 AM |
| Based on the Above Topics-common for CTRT -rt abstracts MO abstracts | 02:49 AM - 03:20 AM |
| HARMONi-2 Trial: Ivonescimab vs. Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results | 03:20 AM - 03:27 AM |
| NVALT-30 Trial (ESMO 2024): Low vs. Standard Dose Pembrolizumab in Stage IV NSCLC | | 03:27 AM - 03:34 AM |
| Pembrolizumab + Chemo in PD-L1 NSCLC | 5-Year Survival Data (Pooled Analysis) | 03:34 AM - 03:41 AM |
| RELATIVITY-104 Trial: Nivolumab + Relatlimab + Chemo vs Nivolumab + Chemo in Stage IV NSCLC | 03:41 AM - 03:48 AM |
| GALAXIES Lung-201 (LBA52): Belrestotug + Dostarlimab in PD-L1 High NSCLC | Interim Phase II Data | 03:48 AM - 03:55 AM |
| TROPION-Lung01 Final OS: Datopotamab Deruxtecan vs Docetaxel in NSCLC | | 03:55 AM - 04:02 AM |
| Akkermansia muciniphila & Multi-Omic Profiling in Advanced NSCLC | ESMO 2024 Abstract 1172O | 04:02 AM - 04:09 AM |
| F. prausnitzii + PD-1 Inhibitors: Boosting Immunotherapy in NSCLC? | 04:09 AM - 04:16 AM |
| Treatment Strategies for Driver-Negative Metastatic NSCLC | | 04:16 AM - 04:45 AM |
Program Director:
Undiscolosed
Contact Person
Undisclosed
noreply@crsf.in
0000000000
Download